

**LACHMAN CONSULTANT SERVICES, INC.**  
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590  
(516) 222-6222 • FAX (516) 683-1887

2013 OCT 22 A 10: 06

October 21, 2013

**OVERNIGHT COURIER 10/21/13**

Division of Dockets Management (HFA-305)  
Food and Drug Administration  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20552

**CITIZEN PETITION**

Dear Sir or Madam:

Lachman Consultant Services, Inc. ("Lachman") is submitting this Citizen Petition in quadruplicate pursuant to 21 § C.F.R. 10.30 and in accordance with the regulations of 21 § C.F.R. 314.161, on behalf of a client, to request that the Commissioner of the Food and Drug Administration determine whether a listed drug has been voluntarily withdrawn for safety or effectiveness reasons as outlined below.

**A. Action Requested**

The petition requests that the Commissioner of the Food and Drug Administration determine whether PREZISTA® (darunavir) Tablets, 400 mg has been voluntarily withdrawn from sale for safety or efficacy reasons.

**B. Statement of Grounds**

The Food and Drug Administration maintains a list of drug products that are eligible for submission as abbreviated new drug applications in the *Approved Drug Products with Therapeutic Equivalence Evaluations* ("The Orange Book"). PREZISTA® (darunavir) Tablets, 400 mg, by Janssen, was approved by the FDA on October 21, 2008, under NDA 21-976. Upon approval, PREZISTA® (darunavir) Tablets, 400 mg was considered to be a "listed drug product" by virtue of its listing in the Orange Book. While the electronic Orange Book, accessed on October 18, 2013 (current through September 2013) still lists PREZISTA® Tablets, 400 mg as an actively marketed product, Janssen has publically announced that this dosage strength is being discontinued in favor of the 800 mg dosage strength. (Refer to **Attachment 1**). The petitioner believes that the 400 mg dosage strength has been discontinued from the market place for commercial reasons.

Under FDA regulations, drugs are withdrawn from the market if the Agency withdraws or suspends approval of the drug application for the reasons of safety or effectiveness, or if the FDA determines that the listed drug was withdrawn or withheld from sale for reasons of safety or effectiveness (21 C.F.R. § 314.162). The regulations also provide that the Agency must make a determination as to whether a listed drug is withdrawn from sale for reasons of safety or effectiveness before an ANDA that refers to that listed drug may be approved (21 § C.F.R. 314.161(a)(1)).

As stated above, at the time of this petition's submission, there is no evidence that Janssen is marketing PREZISTA® (darunavir) Tablets, 400 mg. Accordingly, Lachman respectfully requests that FDA determine whether PREZISTA® Tablets, 400 mg was discontinued for reasons of safety or efficacy reasons, in order to enable action on an ANDA referring to PREZISTA® Tablets, 400 mg as the Reference Listed Drug. Should the NDA holder recommence marketing its 400 mg strength of

FDA-2013-P-1379

[www.lachmanconsultants.com](http://www.lachmanconsultants.com)

[LCS@lachmanconsultants.com](mailto:LCS@lachmanconsultants.com)

2013-8820  
CF

PREZISTA® Tablets after the submission of this petition and prior to an FDA response, and there is evidence that the product is available in the marketplace, Lachman will consider this petition moot. Lachman will, at that time, take the appropriate action to request withdrawal of the petition.

**C. Environmental Impact**

A claim for categorical exclusion of the requirements for an environmental assessment is made pursuant to 21 C.F.R. § 25.31.


**D. Economic Impact**

Pursuant to 21 C.F.R. § 10.30(b), economic impact information is submitted only when requested by the Commissioner. This information will be promptly provided, if so requested.

**E. Certification**

The undersigned certifies that, to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petition which is unfavorable to the petition.

Respectfully submitted,

  
Joan Janulis, R.A.C.  
Vice President

JJ/pk

Attachments: Johnson & Johnson press release, dated 11/9/12, "FDA Approves New 800 mg  
PREZISTA® (darunavir) Tablet"  
Dosing information at [www.prezista.com/healthcare/treatmentexperienced/dosing](http://www.prezista.com/healthcare/treatmentexperienced/dosing)

cc: Martin Shimer (Office of Generic Drugs)

*Petition Darunavir 102113*

From: (516) 663-1881  
 Westbury Office  
 LACHMAN CONSULTANT SERVICES  
 1800 STEWART AVE  
 SUITE 604  
 WESTBURY, NY 11590

Origin ID: RMEA



Ship Date: 21OCT13  
 ActWgt: 1.0 LB  
 CAD: 105332656/NET3430

Delivery Address Bar Code



SHIP TO: (301) 827-6860  
**Division of Dockets Management**  
**FDA, DHHS, HFA-305**  
**5630 FISHERS LN RM 1061**

BILL SENDER

ROCKVILLE, MD 20852

Ref # Citizen Petition  
 Invoice #  
 PO #  
 Dept #

TUE - 22 OCT AA  
 STANDARD OVERNIGHT

DSR  
 20852  
 MD-US  
 IAD

TRK# 7969 6017 8738  
 0201

**EP NSFA**

51AG1/AB1B/1ABE

**After printing this label:**

1. Use the 'Print' button on this page to print your label to your laser or inkjet printer.
2. Fold the printed page along the horizontal line.
3. Place label in shipping pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned.

**Warning:** Use only the printed original label for shipping. Using a photocopy of this label for shipping purposes is fraudulent and could result in additional billing charges, along with the cancellation of your FedEx account number.

Use of this system constitutes your agreement to the service conditions in the current FedEx Service Guide, available on [fedex.com](http://fedex.com). FedEx will not be responsible for any claim in excess of \$100 per package, whether the result of loss, damage, delay, non-delivery, misdelivery, or misinformation, unless you declare a higher value, pay an additional charge, document your actual loss and file a timely claim. Limitations found in the current FedEx Service Guide apply. Your right to recover from FedEx for any loss, including intrinsic value of the package, loss of sales, income interest, profit, attorney's fees, costs, and other forms of damage whether direct, incidental, consequential, or special is limited to the greater of \$100 or the authorized declared value. Recovery cannot exceed actual documented loss. Maximum for items of extraordinary value is \$1,000, e.g. jewelry, precious metals, negotiable instruments and other items listed in our ServiceGuide. Written claims must be filed within strict time limits, see current FedEx Service Guide.